ghp September 2016 | 69 Chronos Therapeutics Strengthens Management Team with New Appointments Fraser and Timothy join Chronos from Polleo Pharma, a UK biotech start-up company they co-founded. Both have substantial scientific management expertise ac- quired in large pharmaceutical companies and previously held senior positions at Shire, AstraZeneca and Merck. Fraser and Timothy will be responsible for three pre-clinical research programmes recently acquired by Chronos. These include a dopamine active transporter inhibitor programme in MS fatigue and the Company’s orexin 1 antagonist programme in addictive behaviours. A third, undisclosed programme has potential in post-traumatic stress disorder (PTSD). Chronos’ commercial evaluations reveal significant unmet medical needs in these target indications and very substantial commercial potential. Dr Huw Jones, CEO of Chronos Therapeutics, com- mented: “We are delighted to welcome Fraser and Timothy to Chronos at a time of significant expansion of our research portfolio. They bring substantial pre-clin- ical development expertise to our organization and are synergistic to our recent acquisition. In particular, their experience as co-founders of Polleo will be invaluable as we advance our behavioural brain disease portfolio.” Fraser Murray Dr Murray brings more than 20 years’ of drug discovery and early development experience across a range of therapeutic areas, including neurodegen- eration, psychiatry, inflammation and dermatology. He has held leadership roles at Shire, AstraZeneca and Merck. Prior to co-founding Polleo Pharma and raising investment to fund the portfolio, Dr Murray was Senior Director and Head of Discovery Biology for Shire Speciality Pharmaceuticals, focused on CNS and GI disorders. Dr Murray holds a PhD from The School of Pharmacy UCL, a BSc from the University of Strathclyde and an MBA from Alliance Manchester Business School. Timothy Schulz-Utermoehl Dr Schulz-Utermoehl has over 17 years’ experience in the pharmaceutical industry, spanning early and late-stage discovery research and preclinical develop- ment. He has held senior roles at Shire, AstraZeneca and Merck. Prior to co-founding Polleo Pharma, Dr Schulz-Utermoehl was a Director within the Explorato- ry Projects Department for Shire Speciality Pharma- ceuticals in the UK. Dr Schulz-Utermoehl carried out post-doctoral research at Novo Nordisk A/S, holds a PhD in Biochemistry from Imperial College London, an MSc in Toxicology from the Royal Postgraduate Medical School, London and a BSc in Pharmacology/ Physiology from the University of Leeds. For additional information, please visit: www.chronostherapeutics.com Chronos Therapeutics Ltd (Chronos), the private biotech compa- ny focused on ageing diseases, brain and nervous system dis- orders on 4th August announced the appointment of Dr Fraser Murray and Dr Timothy Schulz-Utermoehl, as Vice Presidents of Pre-Clinical Development.